生物试剂
>
生化试剂
>
信号通路
> Sorivudine
加入收藏 取消收藏

Sorivudine  ≥95%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：5mg 10mg 25mg 50mg 100mg in glass bottle
溶解性：溶于DMSO（250 mg/mL 超声）
产品描述：基本信息 产品编号：S10773 产品名称：Sorivudine CAS: 77181-69-2   储存条件 粉末 -20℃ 四年     分子式： C11H13BrN2O6 溶于液体 -80℃ 六个月 分子量 349.13 -20℃ 一个月 化学名：  5-((E)-2-bromovinyl)-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione   Solubility (25°C)   体外 DMSO 100mg/mL (286.43mM; Need ultrasonic) Ethanol   Water   体内 现配现用   ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 2.8643mL 14.3213mL 28.6426mL 5mM 0.5729mL 2.8643mL 5.7285mL 10mM 0.2864mL 1.4321mL 2.8643mL   生物活性 产品描述 一种口服活性的，合成的嘧啶核苷抗代谢 (pyrimidine nucleoside antimetabolite) 药物。 靶点/IC50 DNA/RNA Synthesis   体外研究 Sorivudine (BV-araU) inhibits strains of HSV-1 and HSV-2 (wild-type strains VR-3 and UW-268) with ID50s (50% inhibitory dose) of 0.39 and 0.67μM, respectively. Sorivudine has antiviral activity against several viruses including varicella zoster virus, herpes simplex type 1 virus, and Epstein-Barr virus. Sorivudine (BV-araU) is a pyrimidine nucleoside analog which has in vitro inhibitory activity against varicella zoster virus (VZV) at concentrations of 00001-0.004 mg/ml These concentrations are over 1000-fold lower than those which are required for the inhibition of VZV replication by acyclovir 3 Sorivudine also inhibits HSV-I replication at concentrations ranging from 0.03-0.1mg/ml.   体内研究 Sorivudine (BV-araU) has been evaluated in the treatment of HSV-l encephalitis when administered orally to mice. At dosages in excess of 12.5mg/kg, survival of treated mice is prolonged. With doses in excess of 50mg/kg, a significant decrease in mortality was achieved as we1l. A more relevant model is that of simian varicella virus infection in African green monkeys (Cerophithecus aethiops). In this system, Sorivudine therapy at dosages as low as 20mg/kg per day given intramuscularly or 100mg/kg per day administered orally completely protected against viremia and mortality. In the conduct of these studies, there was no evidence of neurotoxicity or abnormalities in hematology or clinical chemistries. Doses as low as 0.2mg/kg per day were effective; however, breakthrough viremia was noted at lower dosages
保存条件：-20℃

猜你喜欢